-
Real-world Outcomes in Multiple Myeloma
Study shines a light on the differences in outcomes between clinical trial patients with multiple myeloma and those receiving cancer treatment in their community.
by Sandra Gordon
-
January 26: The Week in Cancer News
Questions about screening for women with dense breast tissue, and the FDA asks drugmakers to add a warning to labels for CAR T-cell therapies.
by Thomas Celona
-
Some Breast Cancer Patients May Safely Skip Radiation
Three presentations at SABCS in December find that it may be safe in certain cases for people with breast cancer to go without radiation.
by Cancer Research Catalyst
-
January 19: The Week in Cancer News
Preventive gastrectomy has lasting effects, and rising cancer incidence undercuts continued progress against mortality.
by Eric Fitzsimmons
-
January 12: The Week in Cancer News
Hiding serious illness can be a coping strategy, and cancer rates are on the rise among young people.
by Kevin McLaughlin
-
Doctors Urge Need for ‘Common Sense Oncology’
A movement of health care professionals say the toll of many cancer treatments is out of sync with the purported benefits.
by Kyle Bagenstose
-
January 5: The Week in Cancer News
The FDA will review a blood test that detects colon cancer, and a writer recounts his sister’s decision to receive medical aid in dying.
by Marci A. Landsmann
Previous |
Cancer Talk
Online Second Opinions
More than half of patients who participated in a program offering online second opinions were recommended a change to their treatment plan.
by Eric Fitzsimmons
Musical Toxicity an Effect of Cancer TreatmentStudy finding cancer treatment affects ability to play or sing music highlights need for physical therapy, experts say.
by Kyle Bagenstose
Treatment Lags Behind Guidelines for Many Men With Prostate CancerGuidelines for treating advanced prostate cancer changed in 2017, but a recent study indicated many patients were not being treated accordingly.
by Laura Gesualdi Gilmore
Treating HER2-ultralow Breast CancerFDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon